Clinical Trial Details

EORTC-26071-22072-BTG-ROG

Back to Clinical Trials Database

Cilengitide in subjects with newly diagnosed glioblastoma and methylated MGMT promoter gene- a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone (CENTRIC)

Study documentation

Trial Status LT-FU ongoing
Dates Date of activation: 11-Aug-2008
Date Step1 close: 10-May-2011
Date Step2 close: 06-Jun-2011
Data management at EORTC No
Design Phase 3
Randomized open label
Targeted Sample size All Groups: 504
Treatment Drug
Temozolomide, Cilengitide
Study Staff Vassilis Golfinopoulos (Clinical Research Physician) , EORTC Headquarters, Brussels
Thierry Gorlia (Statistician) , EORTC Headquarters, Brussels
Marie-Ange Lentz (Data Manager) , EORTC Headquarters, Brussels
Sara Meloen (Pharmacovigilance Manager) , EORTC Headquarters, Brussels
Type of cancer Brain
Participating groups EORTC Brain Tumor Group
EORTC Radiation Oncology Group
Protocol summary http://clinicaltrials.gov/ct/show/NCT00689221
NCT number NCT00689221
EudraCT 2007-004344-78
Financial Support Fully supported